Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Warp Speed May Be Usurping BARDA, Potentially Hurting COVID-19 Vaccine Prospects

Executive Summary

Congress wants HHS to explain why BARDA scientists were removed from leadership positions on COVID-19 vaccine contracts. It is just one of multiple examples of Democrats raising concerns that Operation Warp Speed could be hurting, not helping the COVID-19 response effort.

You may also be interested in...



BARDA Funding Freeze Risks Companies Abandoning COVID Therapeutic Work

BARDA’s suspension of funding for COVID-19 therapeutics risks repeating mistakes of past pandemics as it may cause industry to pull out of the development space, experts say. Industry sources are concerned the Biden administration is focusing on funding NIH at the expense of BARDA.

Operation Warp Speed Spreads Its Bets With $1.6bn Novavax Deal

Novavax has progressed into Phase I trials with relatively little funding, but backing from Operation Warp Speed makes it a stronger contender.

Moderna: Speed Of COVID-19 Vaccine Now Hinges On Enrolling The Right Patients

Recruiting the right patient population for Phase III trials of COVID-19 vaccines will be a key factor in how fast any candidate can come to market. The challenge, which will likely mean enrolling patients who often are underrepresented in trials, is keeping Moderna's Chief Medical Officer up at night. The company also talked vaccine distribution, what it feels it owes the US government for its financial support, and pricing of its potential mRNA vaccine on a recent New York Academy of Sciences webinar.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS142448

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel